APAkash Pawar

Akash Pawar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Akash Pawar has a total of 203 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Reply to: Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab

    by Kumar Prabhash, Vanita Noronha, Akash Pawar, Ankush Shetake, Rajendra Badwe

  • Open Access

    Prognostic Reclassification and Survival Outcomes in Intermediate-Risk and Poor-Risk Nonseminomatous Germ Cell Tumors: Single-Institution Experience From Western India

    by Kunal Jobanputra, Aditya Dhanawat, Gagan Prakash, Amandeep Arora, Sayak Dey, Akash Pawar, Bhagyashri Jadhav, Nandini Menon, Minit Shah, Mahendra Pal, et al.

    PURPOSE: Intermediate-risk and poor-risk nonseminomatous germ cell tumors (NSGCTs) have inferior survival outcomes compared with earlier stages. This study reports the survival outcomes and proposes a prognostic reclassification to identify the poorest risk subset within these groups. METHODS: A retrospective analysis was conducted on consecutive patients 15 years and older with intermediate-risk or poor-risk NSGCTs, as per the International Germ Cell Cancer Collaborative Group classification, treated at a tertiary cancer center in western India from 2015 to 2021. Survival outcomes were analyzed using the Kaplan–Meier method, with multivariate analyses identifying prognostic factors. A risk factor model and nomogram were developed and compared with the existing classification. RESULTS: A total of 400 patients were included with a median follow-up of 60.2 months; 5-year overall survival (OS) was 84.6% for intermediate-risk and 52.6% for poor-risk patients ( P < .001). Five-year relapse-free survival (RFS) was 77.0% and 45.6%, respectively ( P < .001). Age 35 years and older; mediastinal primary; and liver, lung, and brain metastases were significant factors for both RFS and OS by multivariate analyses. Additionally, lactate dehydrogenase >10× upper limit of normal was significant for RFS while alpha-fetoprotein >10,000 ng/mL was significant for OS. The risk factor model stratified patients (0, 1, 2, ≥3 factors) with 5-year OS of 90.3%, 69.6%, 53.8%, and 27.1%, respectively, outperforming existing classification (c-index: 0.668 v 0.629 for OS; 0.666 v 0.619 for RFS). A validated nomogram further enhanced prognostic precision. CONCLUSION: This largest single-center Indian cohort of intermediate-risk and poor-risk NSGCTs identifies a “poorest risk” subset who may benefit from treatment intensification and novel strategies.

  • Development of a novel predictive nomogram to prevent ‘futile surgery’ in gallbladder cancers: A single center analysis of 1196 resected gallbladder cancers

    by Gurudutt P. Varty, Shraddha Patkar, Mufaddal Kazi, Karthik Velmurugan, Amita Sekhar Padhy, Baskaran Dhanapal, Sujat Lele, Snigdha Kamini, Abdeali Saif Arif Kaderi, Akash Pawar, et al.


  • Response to Letter Re: “A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer”

    by Kumar Prabhash, Vanita Noronha, Vijay Patil, Nandini Menon, Minit Shah, Ajay Singh, Nikhil Pande, Supriya Goud, Sucheta More, Rangita Sharma, et al.

  • A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer

    by Kumar Prabhash, Vanita Noronha, Vijay Patil, Nandini Menon, Minit Shah, Ajay Singh, Nikhil Pande, Supriya Goud, Sucheta More, Rangita Sharma, et al.


  • Outcomes and recurrence patterns following resection of T1 ampullary carcinomas: single centre experience of 92 cases

    by Gurudutt P. Varty, Arindam Mondal, Siva Sumanth Dukkipati, Akash Pawar, Vikram Chaudhari, Shailesh V. Shrikhande, Manish S. Bhandare


  • Open Access

    Predicting clinical benefit response after neoadjuvant chemotherapy in locally advanced gallbladder cancer: retrospective analysis

    by Shraddha Patkar, Kaival Gundavda, Kaushik Polusany, Raghav Yelamanchi, Gurudutt P Varty, Niket Shah, Akash Pawar, Vikas Ostwal, Anant Ramaswamy, Prabhat Bhargava, et al.

    Background: Neoadjuvant chemotherapy is increasingly used in patients with locally advanced gallbladder cancer (LAGBC). This study investigated factors affecting clinical benefit response (CBR) to neoadjuvant chemotherapy for LAGBC. Methods: All consecutive patients with LAGBC following neoadjuvant chemotherapy, from January 2013 to December 2022, were analyzed for clinical and radiological responses as well as survival outcomes. CBR rates, resectability, and their impact on survival were evaluated. In addition, factors predicting CBR were identified and a predictive nomogram model was developed. Results: Of 401 patients with LAGBC undergoing neoadjuvant chemotherapy, 303 (75.5%) exhibited a CBR. The median overall survival (OS) in patients with a CBR was 25 months, compared with 8.5 months for those without a CBR. Factors predicting a worse CBR rate included age ≥ 55.5 years (hazard ratio (HR) 2.17; 95% confidence interval (c.i.) 1.29 to 3.65), Eastern Cooperative Oncology Group (ECOG) performance status ≥ 1 (HR 2.5; 95% c.i. 1.117 to 5.59), platelet count ≥ 468 × 109/l (HR 2.86; 95% c.i. 1.12 to 6.74), tumour (T) size ≥ 2.1 cm (HR 3.4; 95% c.i. 1.70 to 6.80), T stage ≥ T3 (HR 3.26; 95% c.i. 1.22 to 8.74), and a systemic immune-inflammation index (SII) ≥ 1265.90 (HR 2.34; 95% c.i. 1.27 to 4.30). Of the patients with a CBR, 86% underwent curative surgical resection, with median OS improved to 29.54 months, compared with 11.86 months for those without resection (P < 0.01). Conclusion: A CBR was achieved in 75.5% of patients, with curative surgical resection in 86%. A CBR was associated with improved OS. Anatomical (T size, T stage) and immune–inflammation markers (platelet count, SII) were found to predict a CBR, and could help identify responders to neoadjuvant chemotherapy. This could have implications for treatment strategies, but requires validation in further prospective studies.

  • Comprehensive Genomic Profiling of Indian Patients With Lung Cancer

    by Shivani Sharma, Vanita Noronha, Arti Yadav, Madhvi Mandhania, Sambit K. Mohanty, Rahul Katara, Aditi Aggarwal, Sagar Samrat Mohanty, Akash Kumar, Sanjeev Kumar, et al.

    PURPOSE: Genomic profiling has revolutionized non–small cell lung cancer (NSCLC) therapy, but molecular data on Indian patients with NSCLC are limited. MATERIALS AND METHODS: We analyzed next-generation sequencing (NGS) data of 5,219 Indian patients with lung cancer, tested between May 2022 and August 2023 at CORE Diagnostics, a commercial laboratory in India. Using the PulmoCORE gene panel, we targeted 13 key genes ( ALK , BRAF , EGFR , ERBB2 , KRAS , MAP2K1 , MET , NRAS , PIK3CA , RET , ROS1 , TP53 , and NTRK ) for DNA and RNA sequencing. PD-L1 was tested by immunohistochemistry. RESULTS: Median patient age was 62 years, and 62.5% were male. Common histologies included adenocarcinoma (57.1%), NSCLC not otherwise specified (19.3%), and squamous cell carcinoma (7%). Genomic alterations were detected in 80.6% patients according to the PulmoCORE panel; 64.2% patients had actionable alterations in at least one of the nine biomarkers with Food and Drug Administration–approved targeted therapies, that is, EGFR , KRAS , ALK , ROS1 , BRAF , NTRK1/2/3 , MET , RET , and ERBB2 . Common alterations included TP53 (37%), EGFR (34.1%), and KRAS (13.3%), ALK (8.8%), and others below 5%. Alterations were more common in adenocarcinoma (76.4%) than in patients with squamous cell carcinoma (29.9%). Sex and age influenced mutation prevalence, with EGFR mutations more common in females and KRAS in males, while ALK , ROS1 , and RET fusions were prevalent in younger adults. Most genomic alterations were mutually exclusive, although 25% patients had co-occurring mutations. PD-L1 positivity was higher in males (28.3%) and more common in patients with squamous cell carcinoma (34.2%). CONCLUSION: Broad molecular profiling is important to detect actionable alterations in Indian patients with lung cancer, for delivering optimal personalized precision medicine. Our study underscores the fact that NGS should be routinely done before planning therapy in Indian patients with advanced lung cancer.


  • Real-World Analysis Evaluating Treatment Eligibility and Outcomes in Patients With AML Receiving Intensive Chemotherapy: Insights From an Underrepresented Population

    by Hasmukh Jain, Thomas Eipe, Alok Shetty, Lingaraj Nayak, Bhausaheb Pandurang Bagal, Neha Sharma, Akash Pawar, Manju Sengar

    PURPOSE: Over the past decade, there have been significant advancements in the treatment of AML. However, similar progress has not been observed in India, with induction mortality rates surpassing those in high-income countries. Our patient population also differs significantly from those in clinical trials, with about 50% ineligible for intensive chemotherapy. Yet, because of limited access to newer therapies and high costs, most of these patients receive intensive therapy. PATIENTS AND METHODS: In this study, we retrospectively classified patients who received intensive induction into fit and unfit groups on the basis of landmark trial criteria. Data were extracted from the Indian Acute Leukemia Research Database, a prospective registry maintained under the Hematology Cancer Consortium. The primary objective was induction mortality. RESULTS: We analyzed 385 patients with AML treated between 2017 and 2019. The median age at diagnosis was 33 years (range, 15-61). Induction mortality was reported at 6.1% in the fit cohort and 20.2% in the unfit cohort (odds ratio, 3.91 [1.97-7.74]; P < .0001). Factors such as increased age, poor performance status, baseline infection, and low albumin were associated with a poor prognosis for early death. After a median follow-up of 19.2 months, the 2-year overall survival in the overall, fit, and unfit cohorts was 62.7%, 67%, and 58.1%, respectively. CONCLUSION: Our findings highlight the baseline characteristics of our patient population and their impact on the outcomes of induction therapy. Unfit patients who received intensive chemotherapy had higher induction mortality and lower overall survival.


  • Adenosquamous carcinoma of the gallbladder: a Bi-institutional experience in managing this rare entity

    by Gurudutt P. Varty, Shraddha Patkar, Sujat Lele, Swapnil Patel, Gauri Deshpande, Ipsita Dhal, Mufaddal Kazi, Akash Pawar, Vikas Ostwal, Anant Ramaswamy, et al.